Twitter LinkedIn
Return to Wellspring


Combination Therapeutic Nanoparticle Platform Drug Delivery System


Project TitleCombination Therapeutic Nanoparticle Platform Drug Delivery System
Track Code2045
Short Description

The technology is a combined nanoparticle system with both anti-inflammatory and chemotherapeutic properties. Prostate cancer is one of the most frequently diagnosed and deadly forms of cancer affecting men in the United States and around the world.  Nanotechnology has recently emerged as a promising method for the delivery of multiple drugs with high efficiency.  Nanoparticles based on the Food and Drug Administration (FDA) approved polymers such as poly(lactide-co-glycolide) (PLGA) and poly(ethyleneglycol) (PEG) have shown exceptional ability to enter tumor tissues through enhanced permeability and retention effect and release therapeutics in a controlled fashion


Based on the above premises, UGA researchers have designed a controlled-release, highly functionalized nanoparticle platform drug delivery system with the capabilities to deliver synergistic combinations of chemotherapeutics, anti-inflammatory agents, and bone resorption inhibitors.  These nanoparticles can be used for the treatment of cancers, including one of the deadliest forms of cancer, castration-resistant prostate cancer (CRPC).  This technology can combine two or more cancer therapeutics, with the potential to lead to enhanced patient outcome and it provides for controlled spatio-temporal release of different therapeutics, resulting in more targeted delivery and reduced toxicity. The invention is applicable to a wide range of cancer types, at different stages. The central advantage of this technology over others is that the anti-inflammatory and chemotherapeutic components are encapsulated separately and then covalently linked.  This allows customized doses of each of these components for combined therapeutic applications. In vitro proof-of-concept data generated for prostate cancer cell lines has been achieved.

References and Intellectual Property


Tagscancer therapeutic, nanomedicine, inflammation
Posted DateNov 14, 2017 12:05 PM


Rachael Widener


File Name Description
2045 Dhar RW.doc None Download